Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD22 CAR T-cells in B-cell Malignancies
NCT04163575Phase 2Unknown
- Sponsor
- Beijing Kecellitics Biotech Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of anti-CD22 CAR T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), sponsored by Beijing Kecellitics Biotech Co., Ltd.. Status: unknown.
02
Drugs
anti-CD22 CAR T cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04163575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163575.